Orlando, FLNCT06993454Now EnrollingIRB Ready

Type 2 Diabetes Clinical Trial in Orlando, FL

Access cutting-edge type 2 diabetes treatment through this clinical trial at a research site in Orlando. Study-provided care at no cost to qualified participants.

Sponsored by AdventHealth Translational Research Institute

Quick Self-Assessment

See if you qualify for this Orlando location

Preparing your pre-screening questions…

Expert Care in Orlando

Access type 2 diabetes specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related type 2 diabetes treatment provided free

Apply for This Orlando Location

Check if you qualify for this type 2 diabetes clinical trial in Orlando, FL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Orlando

    Convenient for FL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Orlando site if eligible
  4. 4Begin participation

About This Type 2 Diabetes Study in Orlando

The overall aim of this study is to investigate the effects of exercise on the amount of glucose that is made by the liver in people with and without Type 2 diabetes (T2D) and hepatic steatosis (fatty liver).

Sponsor: AdventHealth Translational Research Institute

Who Can Participate

Inclusion Criteria

for individuals with T2D and elevated liver fat ≥5.6%
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or (pre-menopausal) female, aged 25-55 years
Body mass index (BMI) between 25 and 45 kg/m2
Sedentary (1 day or less per week of structured exercise)
Type 2 diabetes mellitus: HbA1c ≥7.5%
Liver fat ≥5.6% based on MRI
Weight stable (± 2 kg) for prior 3 months Inclusion criteria for lean, healthy controls
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or (pre-menopausal) female, aged 25-55 years
Body mass index (BMI) between 18.5 and 27.5 kg/m2
Normal liver fat (FibroScan CAP \<249dB/m, \<5.6% liver fat based on MRI)
Weight stable (± 2 kg) for prior 3 months
Active (≥3 day/week of structured exercise)

Exclusion Criteria

Any change in glucose-lowering medications within the previous three months.
Inability to stop any medications which interfere with glucose metabolism for visits 4 and 7.
Resting blood pressure ≥ 160/100 mm Hg
Triglycerides ≥ 500 mg/dL
Any renal, cardiac, liver, lung, or neurological disease that in the opinion of the principal investigator would compromise participant safety or the participants' ability to complete the exercise protocol
Any significant disease or unstable medical condition (i.e., coronary heart disease, chronic renal failure, chronic hepatic disease, severe pulmonary disease)
Presence of clinically significant abnormalities on electrocardiogram (ECG) that is a contra-indication to exercise testing
Cancer (active malignancy with or without concurrent chemotherapy; except for basal cell carcinoma)
Pregnancy during the previous 6 months, lactating, or planned pregnancy in the next 6 months
Post- or peri-menopausal women
Partial and/or full hysterectomy (self-report)
Use of drugs known to affect energy metabolism or body weight: including, but not limited to orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc
Hyperthyroidism including those with normal TSH (0.35-4.5) on pharmacological treatment; individuals with hypothyroidism may be referred to their primary care provider for evaluation and retested; any medication change for hypothyroidism must be stable for ≥3 months prior to retesting
Current treatment with blood thinners or anti-platelet medications that cannot be safely stopped for testing procedures
New onset (\<3 months on a stable regime) hormone replacement therapy
Current use of beta-adrenergic blocking agents
Major surgery on the abdomen, pelvis, or lower extremities within previous 3 months
Previous bariatric or other surgery for obesity
Abnormal blood count/anemia (hemoglobin \<12 g/dl in men or 11 g/dl in women; Hct \<34%), blood transfusion or blood donation within the last 2 months
Current smokers (smoking within the past 3 months prior to screening visit, including any/all tobacco products)
Current drug or alcohol abuse/dependence, or positive urine toxicology screen
Alcohol consumption \>7 drinks per week for women or 14 drinks per week for men or history of binge drinking (≥5 drinks for males or 4 drinks for females in a 2-hour period more than once per month)
Metal implants (pacemaker, aneurysm clips) based on investigator's judgment at screening
Not physically capable of performing the exercise required of the study protocols
Unable to participate in Magnetic Resonance Imaging (MRI) assessments due to physical limitations of equipment tolerances (e.g. MRI bore size) based on investigator's judgment at screening.
Unable to tolerate MRI or claustrophobia.
Diagnosed psychotic or psychiatric conditions prohibiting adherence to study protocol; hospitalization for any psychotic or psychiatric condition within one year
Self-reported chronic, active, or latent infection requiring chronic antibiotic or anti-viral treatment; Human Immunodeficiency Virus (HIV); active hepatitis B or C undergoing antiviral therapy
Unable or unwilling to communicate with staff or to provide written informed consent Exclusion criteria for lean, healthy controls
Currently taking insulin, injectable incretin mimetics, and/or thiazolidinediones
Taking glucose-lowering medications
HbA1c ≥ 5.7%; pre-diabetes, type 2 diabetes, or type 1 diabetes
Resting blood pressure ≥ 160/100 mm Hg
Triglycerides ≥ 500 mg/dL
Any renal, cardiac, liver, lung, or neurological disease that in the opinion of the principal investigator would compromise participant safety or the participants' ability to complete the exercise protocol
Any significant disease or unstable medical condition (i.e., coronary heart disease, chronic renal failure, chronic hepatic disease, severe pulmonary disease)
Presence of clinically significant abnormalities on electrocardiogram (ECG) that is a contra-indication to exercise testing
Cancer (active malignancy with or without concurrent chemotherapy; except for basal cell carcinoma)
Pregnancy during the previous 6 months, lactating, or planned pregnancy in the next year
Post- or peri-menopausal women
Partial and/or full hysterectomy (self-report)
Use of drugs known to affect energy metabolism or body weight: including, but not limited to orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc
Hyperthyroidism including those with normal TSH (0.35-4.5) on pharmacological treatment; individuals with hypothyroidism may be referred to their primary care provider for evaluation and retested; any medication change for hypothyroidism must be stable for ≥3 months prior to retesting
Current treatment with blood thinners or anti-platelet medications that cannot be safely stopped for testing procedures
New onset (\<3 months on a stable regime) hormone replacement therapy
Current use of beta-adrenergic blocking agents
Major surgery on the abdomen, pelvis, or lower extremities within previous 3 months
Previous bariatric or other surgery for obesity
Increased liver function tests (AST/ALT/GGT/or alkaline phosphatase greater than 2.5 times the upper limit of normal)
Abnormal blood count/anemia (hemoglobin \<12 g/dl in men or 11 g/dl in women; Hct \<34%), blood transfusion or blood donation within the last 2 months
Current smokers (smoking within the past 3 months prior to screening visit, including any/all tobacco products)
Current drug or alcohol abuse/dependence, or positive urine toxicology screen
Alcohol consumption \>7 drinks per week for women or 14 drinks per week for men or history of binge drinking (≥5 drinks for males or 4 drinks for females in a 2-hour period more than once per month)
Metal implants (pacemaker, aneurysm clips) based on investigator's judgment at screening
Not physically capable of performing the exercise required of the study protocols
Unable to participate in Magnetic Resonance Imaging (MRI) assessments due to physical limitations of equipment tolerances (e.g. MRI bore size) based on investigator's judgment at screening.
Unable to tolerate MRI or claustrophobia.
Diagnosed psychotic or psychiatric conditions prohibiting adherence to study protocol; hospitalization for any psychotic or psychiatric condition within one year
Self-reported chronic, active, or latent infection requiring chronic antibiotic or anti-viral treatment; Human Immunodeficiency Virus (HIV); active hepatitis B or C undergoing antiviral therapy
Unable or unwilling to communicate with staff or to provide written informed consent

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Orlando?

Yes, this clinical trial (NCT06993454) has an active research site in Orlando, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Type 2 Diabetes Treatment Options in Orlando, FL

If you're searching for type 2 diabetes treatment options in Orlando, FL, this clinical trial (NCT06993454) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Orlando research site is actively enrolling participants for this clinical trial. You'll receive care from experienced type 2 diabetes specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all type 2 diabetes clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in Orlando, FL

See all pulmonary embolism clinical trials recruiting in Orlando — not just this study.

Browse Pulmonary Embolism Trials in Orlando →

Browse More Trials by Condition

Pulmonary Embolism TrialsEssential Tremor TrialsType 2 Diabetes TrialsAll Conditions →

Ready to Join in Orlando?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Orlando, FL